United Therapeutics (UTHR) fundamentals: P/E, valuation, undervalued?
United Therapeutics · Health Care · ref. ETF XLV · price $527.91
In short — United Therapeutics trades at 18.5× earnings (P/E), 17.6× forward, with a net margin of 41.6 % and revenue growth of -2 %. Read: Fairly valued (P/E 18 in line with ~13% growth (PEG 1.3)).
Is United Therapeutics stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$527.91+71.8% over range
Aug 28, 25low $304.76 · high $596.76Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
78% recommend buying · 9 analysts
Valuation : Fairly valued — P/E 18 in line with ~13% growth (PEG 1.3)
Valuation
18.5
P/E (price/earnings)
17.6
Forward P/E
1.38
PEG
3.5
Price/book (P/B)
$22.6B
Market cap
28.51
EPS
Profitability & growth
41.6 %
Net margin
-2 %
Revenue growth
+13 %
Earnings growth
$0
Total debt
United Therapeutics income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.9B | $727M | 37.6 % |
| 2023 | $2.3B | $985M | 42.3 % |
| 2024 | $2.9B | $1.2B | 41.5 % |
| 2025 | $3.2B | $1.3B | 41.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is United Therapeutics's P/E and is the stock undervalued? What's a good P/E?
United Therapeutics's P/E is 18.5 (forward 17.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is United Therapeutics profitable?
United Therapeutics has a net margin of 41.6 % (EPS 28.51). The company is profitable.
Is UTHR stock expensive?
Our read: "Fairly valued" — P/E 18 in line with ~13% growth (PEG 1.3). Cross-check with growth and sector.
💬 A question about United Therapeutics? The JPI assistant answers using our backtest data.
Keep exploring United Therapeutics